SOURCE: Equity News Circuit

Equity News Circuit

May 28, 2013 08:20 ET

Free Research Reports on BLDP, CLNT, RNIN and VRX Issued by the Paragon Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

NEW YORK, NY--(Marketwired - May 28, 2013) - The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Paragon is an essential resource for hundreds of thousands of investors across the country.

Ballard Power Systems Inc. (NASDAQ: BLDP) (TSX: BLD) shares surged 15.83 percent on volume of 2.93 million shares traded Friday. The stock traded in the range of $1.19 to $1.40 before settling to close at $1.39. The company anticipates that it will power 80 percent of European fuel cell buses used in public transit revenue service in 2014.

Find out more about Ballard Power Systems including full access to the free equity report at:

Cleantech Solutions International Inc. (NASDAQ: CLNT) shares declined 7.02 percent on volume of 1.75 million shares traded Friday. The stock traded in the range of $7.37 to $8.89 before settling to close at $7.68. Shares of Cleantech Solutions soared earlier this month after announcing it has become a certified supplier to China's oil and natural gas industry.

Find out more about Cleantech Solutions including full access to the free equity report at:

Wireless Ronin Technologies, Inc. (NASDAQ: RNIN) shares declined 29.37 percent on volume of nearly 600,000 shares traded to close at $1.01 a share. The company has been notified by the NASDAQ Stock Market that trading on the NASDAQ will be suspended effective with the open of trading on May 31, 2013. The stock will be moved to OTCQB.

Find out more about Wireless Ronin Technologies including full access to the free equity report at:

Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) shares gained 13.12 percent on volume of 10.38 million shares traded to close at $84.47 Friday. According to a recent Wall Street Journal article, the company is close to purchasing eye care company Bausch & Lomb Inc. for approximately $9.0 billion.

Find out more about Valeant Pharmaceuticals including full access to the free equity report at:

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information